Abstract: The invention relates to the use of inorganic aerogels as an auxiliary and/or excipient for pharmaceutical active compounds and/or preparations.
Type:
Grant
Filed:
September 22, 1997
Date of Patent:
August 28, 2001
Assignee:
Hoechst Aktiengesellschaft
Inventors:
Fritz Schwertfeger, Andreas Zimmermann, Harald Krempel
Abstract: The invention relates to monoclonal and polyclonal antibodies, and their parts, which bind specifically to the nidogen-binding domain of laminin, to processes for their preparation and to their use as pharmaceuticals, as diagnostic agents for detecting laminin isoforms and as model substances for developing and evaluating substances which affect the nidogen/laminin interaction. The antibodies according to the invention, or their parts, bind preferentially to the laminin &ggr;1 III 4 domain, in particular in the highly conserved region of the a and c loops, and are able to inhibit the association of laminin and nidogen.
Abstract: A cellulose-hydrate-based food casing impregnated on its inside with liquid smoke which has a pH of about 2 to less than 4 and additionally contains a viscosity-increasing compound, an emulsifier and a triglyceride or lecithin.
Abstract: The invention relates to a method of controlling a biological wastewater purification plant, in which the wastewater is aerated in an activation tank in the presence of an activated sludge and, to influence the properties of the activated sludge, phosphorus is added under controlled concentration, which comprises measuring the phosphorus concentration in the activated sludge for the control of the phosphorus addition and controlling the phosphorus addition in such a manner that the phosphorus concentration in the activated sludge is greater than or equal to a lower limit and is less than or equal to an upper limit. By means of the method according to the invention, the effluent values of a biological wastewater purification plant can be optimized and the limit values in the effluent of a wastewater purification plant prescribed by the authorities can be complied with better than hitherto.
Abstract: The novel molding made from a combination of polyacetal with directly molded-on function elements is distinguished by the fact that the function elements comprise one or more elastomers. Such elastomers comprise partially or fully hydrogenated nitrile rubbers, one- or multicomponent silicone rubbers or sulfur-containing rubbers.
Type:
Grant
Filed:
March 30, 2000
Date of Patent:
May 1, 2001
Assignee:
Hoechst Aktiengesellschaft
Inventors:
Frank Reil, Frank Reuter, Ulrich Haack, Gerhard Reuschel
Abstract: An enhancer has been located in the upstream region of the major immediate early gene of human cytomegalovirus and has been isolated, which enhancer is more active than that from SV40 and has a wide host cell spectrum. Hence, it is suitable for eukaryotic expression systems wherein it can be incorporated upstream or downstream of the structural gene or of the regulation region.
Type:
Grant
Filed:
November 9, 1994
Date of Patent:
April 17, 2001
Assignee:
Hoechst Aktiengesellschaft
Inventors:
Bernhard Fleckenstein, Walter Schaffner, Frank Weber, Karoline Dorsch-Häsler, Gerhard Jahn, Michael Boshart
Abstract: The present invention relates to compounds of the formula I,
A—B—D—E—F—G (I)
in which A, B, D, E, F and G have the meanings given in the patent claims, to their preparation and to their use as medicaments. The compounds of the invention are used as vitronectin receptor antagonists and as inhibitors of bone resorption.
Type:
Grant
Filed:
October 5, 1999
Date of Patent:
April 17, 2001
Assignees:
Hoechst Aktiengesellschaft, Genetech, Inc.
Inventors:
Volkmar Wehner, Hans Ulrich Stilz, Anuschirwan Peyman, Karlheinz Scheunemann, Jean-Marie Ruxer, Denis Carniato, Jean-Michel Lefrancois, Thomas Richard Gadek, Robert McDowell
Abstract: Novel inhibitors of bone reabsorption and antagonists of vitronectin receptors
The present invention relates to 5-membered ring heterocycles of the formula I,
in which E, F, G, W, Y and Z have the meaning given in the patent claims, to their preparation and to their use as medicaments.
The novel compounds are used as vitronectin receptor antagonists and as inhibitors of bone reabsorption.
Type:
Grant
Filed:
March 20, 1997
Date of Patent:
April 17, 2001
Assignees:
Hoechst Aktiengesellschaft, Genetech, Inc.
Inventors:
Volkmar Wehner, Jochen Knolle, Hans Ulrich Stilz, Denis Carniato, Jean-Francois Gourvest, Tom Gadek, Robert McDowell
Abstract: Theophylline derivatives having at least one ether function in the structurally modified methyl radical in the 1-position that are useful in the treatment and prophylaxis of states of shock, new xanthine compounds having this substitution pattern, and processes for their preparation.
Type:
Grant
Filed:
June 4, 1997
Date of Patent:
April 10, 2001
Assignee:
Hoechst Aktiengesellschaft
Inventors:
Ulrich Gebert, Erhard Wolf, Elisabeth Defossa, Uwe Heinelt, Hiristo Anagnostopulos, Karl Rudolphi, John J. Grome
Abstract: Thermoplastic cycloolefin copolymers (COCs) having high tear strength and low optical attenuation, a process for their preparation, and their use as optical waveguides (optical fibers).
Type:
Grant
Filed:
April 28, 1997
Date of Patent:
April 10, 2001
Assignee:
Hoechst Aktiengesellschaft
Inventors:
Michael-Joachim Brekner, Hellmuth Deckers, Frank Osan
Abstract: In order to produce a polymer electrolyte membrane from sulfonated, aromatic polyether ketone, an aromatic polyether ketone of the formula (I)
in which
Ar is a phenylene ring having p- and/or m-bonds,
Ar′ is a phenylene, naphthylene, biphenylene, anthrylene or another divalent aromatic unit,
X, N and M, independently of one another are 0 or 1,
Y is 0, 1, 2 or 3,
P is 1, 2, 3 or 4,
is sulfonated and the sulfonic acid is isolated. At least 5% of the sulfonic groups in the sulfonic acid are converted into sulfonyl chloride groups, and these are reacted with an amine containing at least one crosslinkable substituent or a further functional group, and unreacted sulfonyl chloride groups are subsequently hydrolyzed. The resultant aromatic sulfonamide is isolated and dissolved in an organic solvent, the solution is converted into a film, and the crosslinkable substituents in the film are then crosslinked.
Type:
Grant
Filed:
October 6, 1997
Date of Patent:
April 10, 2001
Assignee:
Hoechst Aktiengesellschaft
Inventors:
Freddy Helmer-Metzmann, Frank Osan, Arnold Schneller, Helmut Ritter, Konstantin Ledjeff, Roland Nolte, Ralf Thorwirth
Abstract: The invention relates to lipopeptides with very homologous amino-acid sequences but different fatty acid residues (lipid portion) which are synthesized by Actinoplanes sp. during fermentation and are released into the culture medium, to a process for isolating the lipopeptides from the culture medium and purifying them, to the use of the lipopeptides as pharmacologically active substances, in particular against Gram-positive bacteria, and to Actinoplanes sp. DSM 7358 for producing the abovementioned lipopeptides.
Type:
Grant
Filed:
March 5, 1997
Date of Patent:
February 27, 2001
Assignee:
Hoechst Aktiengesellschaft
Inventors:
Peter Hammann, Johannes Meiwes, Gerhard Seibert, László Vertesy, Joachim Wink, Astrid Markus
Abstract: Sulfonamide-substituted chromans, processes for their preparation, their use as a medicament or a diagnostic, and medicament comprising them
Chromans of the formula I
and of the formula 1a
having the meanings R(A), R(B), R(C) and R(1) to R(8) indicated in the claims are outstandingly suitable for preparing a medicament for blocking the K+ channel which is opened by cyclic adenosine monophosphate (cAMP); and further for preparing a medicament for inhibiting gastric acid secretion; for the treatment of ulcers of the stomach and of the intestinal region, in particular of the duodenum, for the treatment of reflux esophagitis, for the treatment of diarrheal illnesses, for the treatment and prevention of all types of arrhythmias including ventricular and supraventricular arrhythmias, and for the control of reentry arrhythmias and for the prevention of sudden heart death as a result of ventricular fibrillation.
Type:
Grant
Filed:
February 26, 1999
Date of Patent:
February 20, 2001
Assignee:
Hoechst Aktiengesellschaft
Inventors:
Hans Jochen Lang, Uwe Gerlach, Joachim Brendel, Henrich Christian Englert, Heinz Gögelein, Max Hropot, Helmut Bohn, Andreas Herling, Andreas Busch, Rainer Greger
Abstract: A plastic foam article 1 produced by extrusion, for example, a plastic foam sheet comprising homopolymers and copolymers of polycyclic olefins, contains at least 10% by volume of open cells 2, 4 which have a polyhedron-like shape and adjoin one another. The deformation-free opening of the cells is brought about by means of an extrusion temperature higher than that for the extrusion of thermoplastic plastic foam articles having a closed-cell structure. This leaves webs 3 of cell walls 5, 6 intact in terms of shape, whether they now have openings 7 or have no through passages, so that the mechanical strength of the cell framework or the three-dimensional matrix is retained.
Abstract: A nail varnish comprising glyceryl triacetate as an active compound and a water-insoluble film-forming agent is suitable for treatment of onychomycoses. If appropriate, the nail varnish can also additionally comprise antimycotic 1-hydroxy-2-pyridone derivatives.
Type:
Grant
Filed:
January 11, 1999
Date of Patent:
December 19, 2000
Assignee:
Hoechst Aktiengesellschaft
Inventors:
Manfred Bohn, Karl Theodor Kraemer, Astrid Markus
Abstract: 1,3-Difluoronaphthalene derivatives of the formula (I)R.sup.1 (--A.sup.1 --M.sup.1).sub.a (--A.sup.2 --M.sup.2).sub.b --B(--M.sup.3 --A.sup.3).sub.c (--M.sup.4 --A.sup.4).sub.d --R.sup.2 (I)in whichB is ##STR1## and R.sup.1 (--A.sup.1 --M.sup.1).sub.a (--A.sup.2 --M.sup.2) and (--M.sup.3 --A.sup.3)(--M.sup.4 --A.sup.4)R.sup.2 denote mesogenic radicals are suitable as components for liquid-crystal mixtures, especially ferroelectric mixtures.
Abstract: When herbicides are applied, surfactants can affect the wettability of leaves of the plants and the effectiveness of the herbicides. According to the invention, a particular intensification of action is achieved when surfactants from the group comprising the C.sub.10 -C.sub.18 -alkyl polyglycol ether sulfates and their physiologically acceptable salts together with leaf-acting selective herbicides or the leaf-acting non-selective herbicides glyphosate, paraquat or diquat are applied.
Type:
Grant
Filed:
September 13, 1991
Date of Patent:
December 12, 2000
Assignee:
Hoechst Aktiengesellschaft
Inventors:
Hermann Bieringer, Erwin Hacker, Rudolf Heinrich, Hans-Philipp Huff, Jean Kocur
Abstract: Ortho-substituted benzoylguanidines, process for their preparation, their use as a medicament or diagnostic, and medicament comprising them.Ortho-substituted benzoylguanidines of the formula I ##STR1## in which R(1) to R(4) have the meanings given in the claims, are suitable, as antiarrhythmic pharmaceuticals having a cardioprotective component, for the prophylaxis and treatment of infarction and for the treatment of angina pectoris. They also inhibit, in a preventive manner, the pathophysiological processes associated with the genesis of ischemically induced damage, in particular associated with the triggering of ischemically induced cardiac arrhythmias.
Type:
Grant
Filed:
February 28, 1997
Date of Patent:
November 28, 2000
Assignee:
Hoechst Aktiengesellschaft
Inventors:
Udo Albus, Joachim Brendel, Heinz-Werner Kleemann, Hans Jochen Lang, Wolfgang Scholz, Jan-Robert Schwark, Andreas Weichert
Abstract: The present invention relates to a process for the preparation of hydrophilic hydrogels of high swelling capacity by (co)polymerization of hydrophilic monomers in a fluidized bed apparatus.
Type:
Grant
Filed:
June 23, 1997
Date of Patent:
November 21, 2000
Assignee:
Hoechst Aktiengesellschaft
Inventors:
Fritz Engelhardt, Manfred Mayer, Uwe Nickel